Neoadyuvant therapy with dose-dense (DD) docetaxel (T) and doxorubicin/cyclophosphamide (AC) in locally advanced breast cancer (LABC)
| Autor: | A. García-Palomo, Elvira Alvarez, A. González-Quintas, M. C. Almanza, L. De Paz, M. Ramos, J. R. Mel, Silvia Antolín, L. Calvo Martínez, Jesús García Mata |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Cancer Research
medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Urology Locally advanced Doxorubicin/Cyclophosphamide medicine.disease Surgery medicine.anatomical_structure Breast cancer Oncology Docetaxel Infiltrating ductal carcinoma medicine Bone marrow business Complete response medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 26:11514-11514 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2008.26.15_suppl.11514 |
| Popis: | 11514 Background: Systemic and local therapy is the standard care in the management of LABC. T, A and C have proven efficacy in BC treatment. DD chemotherapy has shown improvement in clinical outcomes for BC. This study was designed to evaluate the efficacy of DD therapy with T × 4 followed by AC × 4. Main objective is pathologic complete response rate. Methods: Women with histologic confirmation of LABC, ECOG PS ≤ 2, age ≥ 18 years and adequate bone marrow, renal, hepatic and cardiac functions were included. Treatment: T 100 mg/m2 iv and prophylactic G-CSF, every 2 weeks × 4 cycles followed by A 60 mg/m2 iv and C 600 mg/m2 iv, every 2 weeks × 4 cycles. Response was evaluated every 4 cycles according to RECIST criteria. Results: Ninety-nine patients (pt) were enrolled, with a median age of 50 years (29–80), ECOG PS was 0/1 86.2/13.8%. Breast locations were left 51.5%, right 46.5% and both 2.0%. Forty-three pt (43.4%) presented stage III breast cancer, 83% had infiltrating ductal carcinoma and 50% were pre... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|